Skip to main content
Premium Trial:

Request an Annual Quote

OncoLens Raises $7.25 Million in Series A Funding

NEW YORK – Health IT startup OncoLens on Wednesday said it has raised $7.25 million in a Series A funding round from investors BIP Capital, Martin Ventures, and SeedToB Capital.

The company's cloud-based software helps cancer centers with tumor board management, workflow automation, survivorship care planning, and clinical decision support. The OncoLens platform specifically facilitates collaboration within multidisciplinary teams by bringing together their patients' clinical data, information from electronic medical records, and test results from genetic information systems. The platform also helps match patients to clinical trials and provides physicians with the latest research or treatment guidelines to guide decision making.

With the shift to telemedicine and virtual care due to the COVID-19 pandemic, OncoLens also helps cancer centers organize virtual tumor board conferences.

"The new investment round will enable us to further capitalize on our position as a leader in the tumor board and cancer treatment planning software industry," Anju Mathew, CEO of OncoLens, said in a statement. "We're excited to continue our work with BIP Capital and our new investors Martin Ventures and SeedToB Capital. Their combined deep expertise in healthcare and AI will help catalyze both our product development and market expansion efforts."

OncoLens, based in Atlanta, is working with several cancer centers in the US, including Georgia-based Emory Healthcare, Pennsylvania-based Tower Health, and MaineGeneral Health, among others. The platform serves more than 8,000 cancer care providers in the US, the company said.